ロード中...
Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors
BACKGROUND: Atypical teratoid/thabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a 5-year overall survival rate of 15%–45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. Th...
保存先:
| 出版年: | Neurooncol Adv |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7236404/ https://ncbi.nlm.nih.gov/pubmed/32642704 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa051 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|